Madhav Madurantakam Royam1, Chellan Kumarasamy2, Siddhartha Baxi3, Ajay Gupta4, Nachimuthu Ramesh1, Gothandam Kodiveri Muthukaliannan1, Rama Jayaraj5. 1. Department of Biotechnology, School of Bio-Sciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, 632014, India. 2. North Terrace Campus, University of Adelaide, Adelaide, SA, Australia. 3. Genesis Cancer Care Centre, Bunbury, Western Australia, 6230, Australia. 4. American Oncology Institute, Nagpur, 530019, India. 5. Department of Clinical Sciences, College of Health and Human Sciences, Yellow 1.1.05, Charles Darwin University, Ellengowan Drive, Darwin, Northern Territory, 0909, Australia. Rama.Jayaraj@cdu.edu.au.
Abstract
BACKGROUND: Findings from observational clinical studies examining the relationship between biomarker expression and theranosis in colorectal cancer (CRC) have been conflicting. OBJECTIVE: We conducted this systematic review and meta-analysis to summarise the existing evidence to demonstrate the involvement of microRNAs (miRNAs) in chemoresistance and sensitivity in CRC through drug genetic pathways. METHODS: Using PRISMA guidelines, we systematically searched PubMed and Science Direct for relevant studies that took place between 2012 and 2017. A random-effects model of meta-analysis was applied to evaluate the pooled effect size of hazard ratios (HRs) across the included studies. Cochran's Q test and the I2 statistic were used to detect heterogeneity. A funnel plot was used to assess potential publication bias. RESULTS: Of the 4700 studies found, 39 studies comprising 2822 patients with CRC met the inclusion criteria. The included studies used one or a combination of 14 chemotherapy drugs, including 5-fluorouracil and oxaliplatin. Of the 60 miRNAs, 28 were associated with chemosensitivity, 20 with chemoresistance, and one with differential expression and radiosensitivity; ten miRNAs were not associated with any impact on chemotherapy. The results outline the importance of 34 drug-regulatory pathways of chemoresistance and sensitivity in CRC. The mean effect size was 0.689 (95% confidence interval 0.428-1.110), indicating that the expression of miRNAs decreased the likelihood of death by about 32%. CONCLUSION: Studies have consistently shown that multiple miRNAs could act as clinical predictors of chemoresistance and sensitivity. An inclusion of supplementary miRNA estimation in CRC routine practice needs to be considered to evaluate the efficacy of chemotherapy after confirming our findings with large-scale prospective cohort studies. PROSPERO REGISTRATION NUMBER: CRD42017082196.
BACKGROUND: Findings from observational clinical studies examining the relationship between biomarker expression and theranosis in colorectal cancer (CRC) have been conflicting. OBJECTIVE: We conducted this systematic review and meta-analysis to summarise the existing evidence to demonstrate the involvement of microRNAs (miRNAs) in chemoresistance and sensitivity in CRC through drug genetic pathways. METHODS: Using PRISMA guidelines, we systematically searched PubMed and Science Direct for relevant studies that took place between 2012 and 2017. A random-effects model of meta-analysis was applied to evaluate the pooled effect size of hazard ratios (HRs) across the included studies. Cochran's Q test and the I2 statistic were used to detect heterogeneity. A funnel plot was used to assess potential publication bias. RESULTS: Of the 4700 studies found, 39 studies comprising 2822 patients with CRC met the inclusion criteria. The included studies used one or a combination of 14 chemotherapy drugs, including 5-fluorouracil and oxaliplatin. Of the 60 miRNAs, 28 were associated with chemosensitivity, 20 with chemoresistance, and one with differential expression and radiosensitivity; ten miRNAs were not associated with any impact on chemotherapy. The results outline the importance of 34 drug-regulatory pathways of chemoresistance and sensitivity in CRC. The mean effect size was 0.689 (95% confidence interval 0.428-1.110), indicating that the expression of miRNAs decreased the likelihood of death by about 32%. CONCLUSION: Studies have consistently shown that multiple miRNAs could act as clinical predictors of chemoresistance and sensitivity. An inclusion of supplementary miRNA estimation in CRC routine practice needs to be considered to evaluate the efficacy of chemotherapy after confirming our findings with large-scale prospective cohort studies. PROSPERO REGISTRATION NUMBER: CRD42017082196.
Authors: Mia C Akerfeldt; Carmen M-N Tran; Clara Shen; Trevor W Hambley; Elizabeth J New Journal: J Biol Inorg Chem Date: 2017-05-17 Impact factor: 3.358
Authors: Joan N Kyula; Sandra Van Schaeybroeck; Joanne Doherty; Catherine S Fenning; Daniel B Longley; Patrick G Johnston Journal: Clin Cancer Res Date: 2010-06-22 Impact factor: 12.531
Authors: Mads H Rasmussen; Niels F Jensen; Line S Tarpgaard; Camilla Qvortrup; Maria U Rømer; Jan Stenvang; Tine P Hansen; Lise L Christensen; Jan Lindebjerg; Flemming Hansen; Benny V Jensen; Torben F Hansen; Per Pfeiffer; Nils Brünner; Torben F Ørntoft; Claus L Andersen Journal: Mol Oncol Date: 2013-02-28 Impact factor: 6.603